This study evaluates the effectiveness and safety of Polatuzumab vedotin plus infusional
chemoimmunotherapy containing rituximab, etoposide, prednisone, cyclophosphamide and
hydroxydaunorubicin. This is a single arm study. Enrolled patients will receive up to six
cycles (21-day cycles) of therapy. While on study, subjects will be monitored weekly until
end of treatment, then followed for 52 weeks or until disease progression or discontinuation
due to toxicity or death.
This is an open label, single arm, phase II investigator initiated clinical trial, evaluating
efficacy and safety of Polatuzumab vedotin added to a modified infusional dose adjusted
R-EPOCH like regimen, given on an inpatient basis, every 21 days, in subjects with Richter's
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.